The National Organization for Rare Disorders (NORD) will celebrate the 35th anniversary of both the 1983 Orphan Drug Act and NORD’s founding at a dinner tonight in Washington, D.C. The 2018 Rare Impact Awards, to be held at the Andrew W. Mellon Auditorium, will be webcast via Facebook for those…
‘Rare Impact Awards’ Dinner Marks Orphan Drug Act and NORD at 35
Investigational SM04646 inhibits expression of TGF-beta-stimulated genes known to promote lung fibrosis, a new study shows. The results will be presented in a poster titled “SM04646 Inhibited Wnt Pathway Gene Expression Stimulated in Response to Transforming Growth Factor-beta and was Effective in a Chronic Model of Bleomycin-induced Pulmonary…
Last week, I wrote about my brain-fog struggles. It’s common to wonder, “Why am I having so much trouble thinking clearly? Is it from pulmonary fibrosis?” I was able to run this question by Noah Greenspan, a doctor of physical therapy who specializes in cardiovascular and pulmonary diseases. He…
Two molecules secreted by epithelial cells of the lungs — CST3 and GDF15 — “are bona fide regulators” of scarring processes and may point to a new way to treat pulmonary fibrosis, an early study reports. The study, “Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics…
Person-first language is a concept that has been around for many years. However, the general population does not prioritize it in everyday language. I don’t believe that people deliberately use disability- or disease-first language, such as “autistic child” or “PF patient.” Rather, I believe person-first language is…
Treatment with Esbriet (pirfenidone, Genentech) or Ofev (nintedanib, Boehringer Ingelheim), or with steroids was found to be safe for idiopathic pulmonary fibrosis (IPF) patients needing a bilateral lung transplant (BLTx), a study reports. The research, “Effect of Antifibrotics on Short-Term Outcome after Bilateral Lung…
The FOXM1 gene is a driver of lung fibroblast proliferation and activation in idiopathic pulmonary fibrosis (IPF), a new study shows. The findings highlight the therapeutic potential of targeting FOXM1 for pulmonary fibrosis treatment. The study “FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis” was published in…
For as long as I can remember, I have always been passionate about traveling. While this has become more difficult since my idiopathic pulmonary fibrosis (IPF) diagnosis, I am grateful that it is not impossible. Having to pull an oxygen concentrator behind me wherever I go was not…
Like many of those living with serious chronic diseases such as idiopathic pulmonary fibrosis (IPF), Marj Korn depends on nurses to help her through the difficult journey. “They have always been kind and made sure to make me as comfortable as possible,” said the former senior recruitment manager. “I need…
The University of Virginia recently launched the Fibrosis Initiative, a platform intended to support and mobilize researchers to collaborate and conduct studies focused on fibrosis. This program is expected to expand knowledge on fibrosis and lead to potentially groundbreaking discoveries that could open up new therapeutic opportunities. “In many…
